Targeted PS delivery could, therefore, be achieved by using bioconjugates where metal-derived compounds are complexed to antibodies that target tumor antigens used in the clinic (e.g., the cetuximab anti-epidermal growth factor receptor (EGFR) or the trastuzumab anti-human epidermal growth factor receptor-2 (HER-2) antibodies). The gene discussed is EGFR; the disease is neoplasm.